<DOC>
	<DOCNO>NCT00135876</DOCNO>
	<brief_summary>In patient malignant glioma , determine efficacy prophylaxis LMWH ( dalteparin ) compare placebo , commence beyond immediate postoperative period , prevention VTE .</brief_summary>
	<brief_title>Dalteparin Low Molecular Weight Heparin Primary Prophylaxis Venous Thromboembolism Brain Tumour Patients</brief_title>
	<detailed_description>Patients randomize 1:1 receive dalteparin 5,000 anti-Xa unit s.c. daily versus placebo s.c. daily . The primary outcome VTE-free survival 6 month . Progression free survival ; overall survival , toxicity , neurocognitive performance secondary outcome measure .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Both following criterion must satisfy : 1 . Patients newlydiagnosed pathologicallyconfirmed WHO Grade 3 Grade 4 glioma ( anaplastic astrocytoma , glioblastoma multiforme , gliosarcoma , anaplastic oligodendroglioma , anaplastic mixed glioma ) . Tumour histology base local pathology review ; 2 . Patients 18 year age old time randomization If one follow criterion satisfy , patient eligible study : 1 . The presence acute chronic DVT demonstrate duplex ultrasonography ( DUS ) venography . ( Note : screening DUS require study entry ) ; 2 . Inability commence study drug within four week original surgery biopsy ; 3 . Serious hemorrhage require hospitalization , transfusion , surgical intervention within four week potential study entry ; 4 . Presence coagulopathy ( e.g . INR &gt; 1.5 platelet count &lt; 100x109/L ) ; 5 . Symptomatic intracranial intratumoural bleeding . ( Note : postoperative image brain require study entry . Asymptomatic “ routine ” postoperative blood product postsurgical cavity exclusion ; 6 . Known acute ( symptomatic actively bleed ) gastroduodenal ulcer ; 7 . Familial bleeding diathesis ; 8 . Requiring long term anticoagulant reason ( e.g. , mechanical heart valve , atrial fibrillation ) ; 9 . Uncontrolled hypertension despite antihypertensive therapy ; 10 . Significant renal failure ( dependent dialysis creatinine great three time upper limit normal control ) ; 11 . Prior history document DVT PE ; 12 . Allergy anticoagulant ( UFH , LMWH ) include immunemediated heparininduced thrombocytopenia ; 13 . Pregnant childbearing potential use adequate contraception ; 14 . Geographically inaccessible followup ; 15 . Having expect life span le 6 month ; 16 . Body weight &lt; 40 kg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>deep vein thrombosis</keyword>
	<keyword>pulmonary embolism</keyword>
	<keyword>glioma</keyword>
	<keyword>fragmin</keyword>
	<keyword>anticoagulant</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>dalteparin</keyword>
</DOC>